Navigating 503A and 503B Not for the Faint of Heart
Published date: December 22, 2020
By David Bronstein
During the Visante Business of Pharmacy Virtual Forum 2020, a topic that stirred considerable discussion was how to stay clear of the financial and regulatory pitfalls of sterile compounding. Whether a health care system operates as a traditional 503A compounder, focusing solely on patient-specific prescriptions, or is considering a 503B build-out to serve multiple facilities within its network, major variables need to be considered.
Read the full article here.
Citation: *Pharmacy Practice News, December 4, 2020*